Amedeo Smart

Free Medical Literature Service

 

Amedeo

Inflammatory Bowel Diseases
  Free Subscription

Articles published in
Am J Gastroenterol
    May 2024
  1. WU S, Liu Y, He Z, Bai Y, et al
    The Association Between Ultra-Processed Foods and Inflammatory Bowel Disease: Far More Complex Than Thought.
    Am J Gastroenterol. 2024 May 3. doi: 10.14309/ajg.0000000000002815.
    >> Share

  2. BERNSTEIN CN, Fisk JD, Dolovich C, Hitchon CA, et al
    Understanding Predictors of Fatigue Over Time in Persons With Inflammatory Bowel Disease: The Importance of Depressive and Anxiety Symptoms.
    Am J Gastroenterol. 2024;119:922-929.
    >> Share

    April 2024
  3. ABREU MT, Kosinski LR
    How Did It Get So Difficult to Care for Patients With Inflammatory Bowel Disease?
    Am J Gastroenterol. 2024 Apr 30. doi: 10.14309/ajg.0000000000002794.
    >> Share

  4. STIDHAM RW, Enchakalody B, Wang SC, Su GL, et al
    Artificial Intelligence for Quantifying Cumulative Small Bowel Disease Severity on CT-Enterography in Crohn's Disease.
    Am J Gastroenterol. 2024 Apr 25. doi: 10.14309/ajg.0000000000002828.
    >> Share

  5. MOHAMED MFH, Marino D, Elfert K, Beran A, et al
    Dye Chromoendoscopy Outperforms High-Definition White Light Endoscopy in Dysplasia Detection for Patients With Inflammatory Bowel Disease: An Updated Meta-Analysis of Randomized Controlled Trials.
    Am J Gastroenterol. 2024;119:719-726.
    >> Share

    March 2024
  6. ALLEGRETTI JR, Axelrad J, Dalal RS, Kelly CR, et al
    Outcomes after Fecal Microbiota Transplantation in combination with Bezlotoxumab for Inflammatory Bowel Disease and Recurrent C . difficile Infection.
    Am J Gastroenterol. 2024 Mar 19. doi: 10.14309/ajg.0000000000002770.
    >> Share

  7. KHAN N, Sundararajan R, Patel M, Trivedi C, et al
    Effectiveness Of Tofacitinib In Ulcerative Colitis Patients: A Nationwide Veterans Administration Cohort study.
    Am J Gastroenterol. 2024 Mar 14. doi: 10.14309/ajg.0000000000002761.
    >> Share

  8. DALAL RS, Kallumkal G, Cabral HJ, Barnes EL, et al
    One-Year Comparative Effectiveness of Upadacitinib Versus Tofacitinib For Ulcerative Colitis: A Multicenter Cohort Study.
    Am J Gastroenterol. 2024 Mar 12. doi: 10.14309/ajg.0000000000002746.
    >> Share

  9. EBACH DR, Jester TW, Galanko JA, Firestine AM, et al
    High Body Mass Index and Response to Anti-TNF Therapy in Pediatric Crohn Disease.
    Am J Gastroenterol. 2024 Mar 6. doi: 10.14309/ajg.0000000000002741.
    >> Share

    February 2024
  10. ANDERSON KL, Anand R, Feuerstein JD
    Insurance Companies' Poor Adherence to Guidelines for Moderate to Severe Ulcerative Colitis/Crohn's Disease Management.
    Am J Gastroenterol. 2024 Feb 29. doi: 10.14309/ajg.0000000000002720.
    >> Share

  11. FRIEDMAN S, Nielsen J, Qvist N, Knudsen T, et al
    Does surgery prior to pregnancy in women with inflammatory bowel disease increase the risk of adverse maternal and fetal outcomes? A Danish national cohort study.
    Am J Gastroenterol. 2024 Feb 20. doi: 10.14309/ajg.0000000000002732.
    >> Share

  12. HERFARTH H
    Dysplasia Detection in Inflammatory Bowel Disease: An Updated Meta-Analysis With Effect.
    Am J Gastroenterol. 2024 Feb 16. doi: 10.14309/ajg.0000000000002658.
    >> Share

  13. SMITH RA, Desai A, Barnes EL, Hayney M, et al
    Patients with Inflammatory Bowel Disease are at Increased Risk for Hospitalization Due to Respiratory Syncytial Virus.
    Am J Gastroenterol. 2024 Feb 6. doi: 10.14309/ajg.0000000000002682.
    >> Share

  14. SUN J, Yao J, Olen O, Halfvarson J, et al
    Long-term risk of myocarditis in patients with inflammatory bowel disease: a nationwide cohort study in Sweden.
    Am J Gastroenterol. 2024 Feb 5. doi: 10.14309/ajg.0000000000002701.
    >> Share

  15. COHEN-MEKELBURG S, Valicevic A, Lin L, Saini SD, et al
    Inflammatory Bowel Disease Hospitalizations are Similar for Patients Receiving Tele-Visit Delivered Outpatient Care and Those Receiving Traditional In-Person Care.
    Am J Gastroenterol. 2024 Feb 5. doi: 10.14309/ajg.0000000000002703.
    >> Share

  16. VAGIANOS K, Dolovich C, Witges K, Graff LA, et al
    Ultra-processed food, disease activity and inflammation in Ulcerative Colitis: The Manitoba Living with IBD Study.
    Am J Gastroenterol. 2024 Feb 2. doi: 10.14309/ajg.0000000000002667.
    >> Share

  17. DRAGONI G, Innocenti T, Amiot A, Castiglione F, et al
    Rates of adverse events in patients with ulcerative colitis undergoing colectomy during treatment with tofacitinib vs biologics: a multicenter observational study.
    Am J Gastroenterol. 2024 Feb 2. doi: 10.14309/ajg.0000000000002676.
    >> Share

  18. ANDREW B, Trinh S, Zhou A, Vasudevan A, et al
    Anal Cancer in Crohn's Disease: The Need to Optimize Treatment and Improve Surveillance.
    Am J Gastroenterol. 2024;119:390-391.
    >> Share

  19. COWARD S, Benchimol EI, Bernstein CN, Avina-Zubieta A, et al
    Forecasting the Incidence and Prevalence of Inflammatory Bowel Disease: A Canadian nationwide analysis.
    Am J Gastroenterol. 2024 Feb 1. doi: 10.14309/ajg.0000000000002687.
    >> Share

  20. FAYE AS, Axelrad JE, Sun J, Halfvarson J, et al
    Atherosclerosis as a Risk Factor of Inflammatory Bowel Disease: A Population-Based Case-Control Study.
    Am J Gastroenterol. 2024;119:313-322.
    >> Share

  21. DALAL RS, Norgard BM, Zegers FD, Kjeldsen J, et al
    Older Adult-Onset of Inflammatory Bowel Diseases Is Associated With Higher Utilization of Analgesics: A Nationwide Cohort Study.
    Am J Gastroenterol. 2024;119:323-330.
    >> Share

  22. FEAGINS LA, Gold S, Steinlauf AF
    Overview of Biosimilars in Inflammatory Bowel Diseases.
    Am J Gastroenterol. 2024;119:229-232.
    >> Share

    January 2024
  23. CHETWOOD JD, Ko Y, Pudipeddi A, Kariyawasam V, et al
    Biological agents in the treatment of Crohn's disease: a propensity score-matched analysis from the prospective Persistence Australian National IBD Cohort (PANIC3) study.
    Am J Gastroenterol. 2024 Jan 26. doi: 10.14309/ajg.0000000000002679.
    >> Share

  24. BERINSTEIN JA, Karl T, Patel A, Dolinger M, et al
    Effectiveness of Upadacitinib for Patients with Acute Severe Ulcerative Colitis: A Multi-Center Experience.
    Am J Gastroenterol. 2024 Jan 26. doi: 10.14309/ajg.0000000000002674.
    >> Share

  25. TANDON P, Huang V, Feig DS, Saskin R, et al
    Recent Immigrants with Inflammatory Bowel Disease Have Significant Health-Care Utilization from Preconception to Postpartum: A Population Cohort Study.
    Am J Gastroenterol. 2024 Jan 23. doi: 10.14309/ajg.0000000000002668.
    >> Share

  26. NARULA N, Wong ECL, Dulai PS, Marshall JK, et al
    Delayed Ustekinumab and Adalimumab Responders Have Similar Outcomes as Early Responders in Biologic-Naive Crohn's Disease.
    Am J Gastroenterol. 2024 Jan 18. doi: 10.14309/ajg.0000000000002654.
    >> Share

  27. MA T, Han D, Sun M
    Acute Pancreatitis After Microscopic Colitis: Is It due to Drugs or Disease?
    Am J Gastroenterol. 2024;119:215-216.
    >> Share

  28. KIWAN W
    Continuing Medical Education Questions: January 2024.
    Am J Gastroenterol. 2024;119:29.
    >> Share

    December 2023
  29. DOLINGER MT, Aronskyy I, Kellar A, Gao M, et al
    Determining the accuracy of intestinal ultrasound scores as a pre-screening tool in Crohn's disease clinical trials.
    Am J Gastroenterol. 2023 Dec 22. doi: 10.14309/ajg.0000000000002632.
    >> Share

  30. SINGH A, Goyal MK, Midha V, Mahajan R, et al
    Tofacitinib in acute severe ulcerative colitis (TACOS): A randomized controlled trial: Tofacitinib in ASUC.
    Am J Gastroenterol. 2023 Dec 22. doi: 10.14309/ajg.0000000000002635.
    >> Share

  31. AFIF W, Arasaradnam RP, Abreu MT, Danese S, et al
    Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-term Maintenance Study.
    Am J Gastroenterol. 2023 Dec 14. doi: 10.14309/ajg.0000000000002621.
    >> Share

  32. WEI L, Patil SA, Cross RK, Taubenslag KJ, et al
    Cystoid macular edema after initiation of ozanimod for ulcerative colitis.
    Am J Gastroenterol. 2023 Dec 12. doi: 10.14309/ajg.0000000000002622.
    >> Share

  33. BOUSVAROS A
    Collaborative Registries for Pediatric Crohn's Disease: A Leap Forward or More of the Same?
    Am J Gastroenterol. 2023 Dec 5. doi: 10.14309/ajg.0000000000002590.
    >> Share

  34. WEISS A, Barnes EL, Bewtra M
    A Practical Guide to the Use of Upadacitinib in Ulcerative Colitis and Crohn's Disease.
    Am J Gastroenterol. 2023 Dec 4. doi: 10.14309/ajg.0000000000002598.
    >> Share

  35. BOURGONJE AR, Mian P
    Identifying Phenotypic Determinants of Infliximab Target Concentrations in Inflammatory Bowel Disease: Toward Personalized Evidence-Based Dosing Regimens.
    Am J Gastroenterol. 2023;118:2308-2309.
    >> Share

  36. DULANEY DT
    Continuing Medical Education Questions: December 2023.
    Am J Gastroenterol. 2023;118:2122.
    >> Share

    November 2023
  37. KAYAL M, Deepak P, Beniwal-Patel P, Raffals L, et al
    Changes in Therapy Are Not Associated with Increased Remission in Patients with Crohn's Disease of the Pouch.
    Am J Gastroenterol. 2023 Nov 17. doi: 10.14309/ajg.0000000000002599.
    >> Share

  38. ANDREW B, Vasudevan A, Srinivasan A
    The Role of Intestinal Ultrasound During Pregnancy in Patients With Inflammatory Bowel Disease.
    Am J Gastroenterol. 2023;118:2096-2097.
    >> Share

  39. BARNES EL, Desai A, Kochhar GS
    The Comparative Effectiveness of Ciprofloxacin and Metronidazole for an Initial Episode of Pouchitis: A Propensity-Matched Study.
    Am J Gastroenterol. 2023;118:1989-1996.
    >> Share

  40. SANTIAGO P, Barnes EL, Raffals LE
    Classification and Management of Disorders of the J Pouch.
    Am J Gastroenterol. 2023;118:1931-1939.
    >> Share

  41. SACHDEVA K, Agarwal S, Kumar P, Mathew D, et al
    Revised Algorithmic Approach to Differentiate Between Nonspecific and Specific Etiologies of Chronic Terminal Ileitis.
    Am J Gastroenterol. 2023;118:2052-2060.
    >> Share

  42. YARUR AJ, Abreu MT, Deepak P, Beniwal-Patel P, et al
    Patients With Inflammatory Bowel Diseases and Higher Visceral Adipose Tissue Burden May Benefit From Higher Infliximab Concentrations to Achieve Remission.
    Am J Gastroenterol. 2023;118:2005-2013.
    >> Share

  43. MOHAN BP, Fatima N, Khan SR, Kassab L, et al
    Early Remission With Induction Therapy Predicts Long-Term Remission in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
    Am J Gastroenterol. 2023;118:2084-2087.
    >> Share

  44. KOCHAR B, Mao EJ, Shah SA
    Optimal Dysplasia Detection and Management in IBD: Now and in the Future.
    Am J Gastroenterol. 2023;118:1905-1908.
    >> Share

  45. DUNLEAVY KA, Cross RK, Raffals LE
    Causes, Diagnostic Testing, and Treatment of Residual Symptoms in Patients With IBD With Quiescent Disease.
    Am J Gastroenterol. 2023;118:1909-1914.
    >> Share

    October 2023
  46. GENERE JR, Ballard DH, Deepak P
    Three-Dimensional Modeling to Guide Interventional Endoscopy in Fibrostenotic Crohn's Disease.
    Am J Gastroenterol. 2023 Oct 13. doi: 10.14309/ajg.0000000000002558.
    >> Share

  47. PHAM JT, Ghusn W, Acosta A, Loftus EV Jr, et al
    Effectiveness and Safety of Antiobesity Medications in Patients With Obesity and Inflammatory Bowel Disease.
    Am J Gastroenterol. 2023 Oct 9. doi: 10.14309/ajg.0000000000002490.
    >> Share

  48. DEBRUYN JC, Huynh HQ, Griffiths AM, Jacobson K, et al
    ADALIMUMAB VERSUS INFLIXIMAB IN LUMINAL PEDIATRIC CROHN'S DISEASE: COMPARABLE OUTCOMES IN A PROSPECTIVE MULTICENTER COHORT STUDY.
    Am J Gastroenterol. 2023 Oct 3. doi: 10.14309/ajg.0000000000002552.
    >> Share

  49. SHUJA A
    Continuing Medical Education Questions: October 2023.
    Am J Gastroenterol. 2023;118:1742.
    >> Share

  50. COELHO-PRABHU N, Lewis JD
    Update on Endoscopic Dysplasia Surveillance in Inflammatory Bowel Disease.
    Am J Gastroenterol. 2023;118:1748-1755.
    >> Share

    September 2023
  51. ALSOUD D, Ho J, Sabino J, Ferrante M, et al
    Utility of the Serum-Based Endoscopic Healing Index in Monitoring Therapeutic Response in Ulcerative Colitis.
    Am J Gastroenterol. 2023 Sep 27. doi: 10.14309/ajg.0000000000002518.
    >> Share

  52. BAK MTJ, Huinink STB, Erler NS, Bodelier AGL, et al
    Prognostic value of the modified Rutgeerts' score for long-term outcomes after primary ileocecal resection in Crohn's disease.
    Am J Gastroenterol. 2023 Sep 22. doi: 10.14309/ajg.0000000000002509.
    >> Share

  53. CAIRNS CA, Cross RK, Khambaty M, Bafford AC, et al
    Monitoring Patients with Inflammatory Bowel Disease at High Risk of Anal Cancer.
    Am J Gastroenterol. 2023 Sep 18. doi: 10.14309/ajg.0000000000002503.
    >> Share

  54. SANTIAGO P, Coelho-Prabhu N, Lennon R, Rui S, et al
    Baseline Clinical Factors are Associated with Risk of Complications in Crohn's Disease: Appraisal of the AGA Clinical Care Pathway.
    Am J Gastroenterol. 2023 Sep 15. doi: 10.14309/ajg.0000000000002498.
    >> Share

  55. WILKERSON RC
    Continuing Medical Education Questions: September 2023.
    Am J Gastroenterol. 2023;118:1543.
    >> Share

  56. KAHN-BOESEL O, Cautha S, Ufere NN, Ananthakrishnan AN, et al
    A Narrative Review of Financial Burden, Distress, and Toxicity of Inflammatory Bowel Diseases in the United States.
    Am J Gastroenterol. 2023;118:1545-1553.
    >> Share

    August 2023
  57. CHANG S, Murphy M, Malter L
    A Review of Available Medical Therapies to Treat Moderate to Severe Inflammatory Bowel Disease in 2023.
    Am J Gastroenterol. 2023 Aug 24. doi: 10.14309/ajg.0000000000002485.
    >> Share

  58. LEVARTOVSKY A, Ben-Horin S, Kopylov U, Klang E, et al
    Towards AI-Augmented Clinical Decision Making: An Examination of ChatGPT's Utility in Acute Ulcerative Colitis Presentations.
    Am J Gastroenterol. 2023 Aug 23. doi: 10.14309/ajg.0000000000002483.
    >> Share

  59. YANG Y, Ludvigsson JF, Olen O, Sjolander A, et al
    Absolute and relative risks of kidney and urological complications in patients with inflammatory bowel disease.
    Am J Gastroenterol. 2023 Aug 10. doi: 10.14309/ajg.0000000000002473.
    >> Share

  60. RAMPERTAB SD
    Continuing Medical Education Questions: August 2023.
    Am J Gastroenterol. 2023;118:1321.
    >> Share

  61. BOPARAI ES, Lee JK, Zhu S, Shirazi A, et al
    The Contemporary Probability of Occult Colorectal Cancer in Patients With Colitis-Related Dysplasia Undergoing Colectomy.
    Am J Gastroenterol. 2023;118:1453-1456.
    >> Share

    July 2023
  62. DUBINSKY M, Bleakman AP, Panaccione R, Hibi T, et al
    Bowel Urgency in Ulcerative Colitis: Current Perspectives and Future Directions.
    Am J Gastroenterol. 2023 Jul 12. doi: 10.14309/ajg.0000000000002404.
    >> Share

  63. FERNANDEZ C, Gajic Z, Esen E, Remzi F, et al
    Preoperative Risk Factors for Adverse Events in Adults Undergoing Bowel Resection for Inflammatory Bowel Disease: 15-Year Assessment of ACS-NSQIP.
    Am J Gastroenterol. 2023 Jul 7. doi: 10.14309/ajg.0000000000002395.
    >> Share

  64. BONFILS L, Sandri AK, Poulsen GJ, Agrawal M, et al
    Medication-wide study: Exploring medication use ten years prior to a diagnosis of inflammatory bowel disease.
    Am J Gastroenterol. 2023 Jul 7. doi: 10.14309/ajg.0000000000002399.
    >> Share

  65. BACHOUR SP, Khan MZ, Shah RS, Joseph A, et al
    Anastomotic configuration and temporary diverting ileostomy do not increase risk for anastomotic stricture in postoperative Crohn's disease.
    Am J Gastroenterol. 2023 Jul 7. doi: 10.14309/ajg.0000000000002393.
    >> Share

  66. VUYYURU SK, Archer M, Nguyen TM, Beaton M, et al
    Long washout periods between biologics for inflammatory bowel disease clinical trials are unnecessary: A Canadian retrospective cohort study.
    Am J Gastroenterol. 2023 Jul 6. doi: 10.14309/ajg.0000000000002398.
    >> Share

  67. BALI AS, Hashash JG, Picco MF, Kinnucan JA, et al
    Electronic Health Record Burden Among Gastroenterology Providers Associated With Subspecialty and Training.
    Am J Gastroenterol. 2023;118:1282-1284.
    >> Share

    June 2023
  68. HU FH, Chen HL
    Low Risk of Lymphoma in Pediatric Patients Treated for Inflammatory Bowel Disease: Need More Evidence.
    Am J Gastroenterol. 2023;118:1101-1102.
    >> Share

  69. DULANEY DT
    Continuing Medical Education Questions: June 2023.
    Am J Gastroenterol. 2023;118:935.
    >> Share

  70. DULANEY DT
    Continuing Medical Education Questions: June 2023.
    Am J Gastroenterol. 2023;118:935.
    >> Share

    May 2023
  71. MARKOVINOVIC A, Quan J, Herauf M, Hracs L, et al
    Adverse Events & Serological Responses Following SARS-CoV-2 Vaccination in Individuals with Inflammatory Bowel Disease.
    Am J Gastroenterol. 2023 May 22. doi: 10.14309/ajg.0000000000002337.
    >> Share

  72. BARNES EL, Zhang X, Long MD, Herfarth HH, et al
    Rate of Colectomy Increases within Twelve Months of Sequential Therapy for Ulcerative Colitis.
    Am J Gastroenterol. 2023 May 22. doi: 10.14309/ajg.0000000000002331.
    >> Share

  73. PARIAN AM, Obi M, Fleshner P, Schwartz DA, et al
    Management of Perianal Crohn's Disease - AJG.
    Am J Gastroenterol. 2023 May 19. doi: 10.14309/ajg.0000000000002326.
    >> Share

  74. LEY D, Leroyer A, Dupont C, Sarter H, et al
    New therapeutic strategies are associated with a significant decrease in colectomy rate in pediatric ulcerative colitis.
    Am J Gastroenterol. 2023 May 4. doi: 10.14309/ajg.0000000000002316.
    >> Share

  75. GOLDOWSKY A, Billings W, Kickel A, Charabaty A, et al
    @MondayNightIBD and the Expanding Gastroenterology Twitterverse: A Study on Continuing Medical Education on #GITwitter.
    Am J Gastroenterol. 2023;118:855-860.
    >> Share

    April 2023
  76. MORTREUX P, Leroyer A, Dupont C, Ley D, et al
    Natural history of anal ulcerations in pediatric-onset Crohn's disease: long-term follow-up of a population-based study.
    Am J Gastroenterol. 2023 Apr 25. doi: 10.14309/ajg.0000000000002301.
    >> Share

  77. COHEN-MEKELBURG S, Van T, Berinstein JA, Yu X, et al
    Characteristics of Facilities with Early and Rapid Ustekinumab Adoption for Patients with Inflammatory Bowel Disease.
    Am J Gastroenterol. 2023 Apr 25. doi: 10.14309/ajg.0000000000002304.
    >> Share

  78. YANG JY, Lund JL, Funk MJ, Hudgens MG, et al
    Utilization of Treat-to-Target Monitoring Colonoscopy after Treatment Initiation in the US-Based Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease (SPARC IBD).
    Am J Gastroenterol. 2023 Apr 13. doi: 10.14309/ajg.0000000000002294.
    >> Share

  79. MARCHEGIANI F, Laurent A, de'Angelis N
    Abdominal mass in a patient with autoimmune hepatitis, ulcerative colitis and BRCA family history - not always what you expect.
    Am J Gastroenterol. 2023 Apr 11. doi: 10.14309/ajg.0000000000002284.
    >> Share

    March 2023
  80. AHUJA D, Murad MH, Ma C, Jairath V, et al
    Comparative Speed of Early Symptomatic Remission with Advanced Therapies for Moderate-Severe Ulcerative Colitis: A Systematic Review and Network Meta-Analysis.
    Am J Gastroenterol. 2023 Mar 29. doi: 10.14309/ajg.0000000000002263.
    >> Share

  81. OGINO T, Mizushima T, Fujii M, Sekido Y, et al
    Crohn's disease-associated anorectal cancer has a poor prognosis with high local recurrence: a subanalysis of the Nationwide Japanese Study.
    Am J Gastroenterol. 2023 Mar 28. doi: 10.14309/ajg.0000000000002269.
    >> Share

  82. ZORZI F, Rubin DT, Cleveland NK, Monteleone G, et al
    Ultrasonographic Transmural healing in Crohn's disease.
    Am J Gastroenterol. 2023 Mar 28. doi: 10.14309/ajg.0000000000002265.
    >> Share

  83. FINE LS, Zhu S, Shirazi A, Lee JK, et al
    Increased Risk of Hospitalization, Surgery and Venous Thromboembolism Among Patients with Inflammatory Bowel Disease and Malnutrition in a Large, Community-Based Healthcare System.
    Am J Gastroenterol. 2023 Mar 9. doi: 10.14309/ajg.0000000000002241.
    >> Share

    February 2023
  84. CARD TR, Nakafero G, Grainge MJ, Mallen CD, et al
    Is Vaccination Against COVID-19 Associated With Inflammatory Bowel Disease Flare? Self-Controlled Case Series Analysis Using the UK CPRD.
    Am J Gastroenterol. 2023 Feb 22. doi: 10.14309/ajg.0000000000002205.
    >> Share

  85. VUYYURU SK, Rieder F, Solitano V, Nguyen TM, et al
    Patients with Crohn's disease and permanent ileostomy are universally excluded from clinical trials: A systematic review.
    Am J Gastroenterol. 2023 Feb 8. doi: 10.14309/ajg.0000000000002215.
    >> Share

  86. MURTHY SK, Benchimol EI
    Low Risk of Lymphoma in Children With IBD Is Reassuring to Clinicians and Families.
    Am J Gastroenterol. 2023;118:261-262.
    >> Share

  87. OTLEY A, Grover Z, Moayyedi P
    Working to Answer the Effectiveness of Nutrition in IBD: Still a Ways to Go.
    Am J Gastroenterol. 2023;118:256-258.
    >> Share

  88. CHO JJ, Pak K, Austin RP, Padilla L, et al
    Endometriosis of the Appendix, Cecum, and Ileum Masquerading as Suspected Crohn's Disease.
    Am J Gastroenterol. 2023;118:197.
    >> Share

  89. OLLECH JE, Yanai H, Avni-Biron I, Snir Y, et al
    Fecal Calprotectin and Quality of Life Questionnaires Are Responsive to Change in Pouch Disease Activity After Antibiotic Therapy: Results From a Prospective Clinical Trial.
    Am J Gastroenterol. 2023;118:367-370.
    >> Share

  90. JOHNSON AM, Barsky M, Ahmed W, Zullow S, et al
    The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium.
    Am J Gastroenterol. 2023;118:317-328.
    >> Share

    January 2023
  91. KAWASAKI K, Kawatoko S, Yamamoto H, Torisu T, et al
    Sessile Serrated Lesion of the Rectum in Ulcerative Colitis Observed by Image-Enhanced Endoscopy.
    Am J Gastroenterol. 2023 Jan 30. doi: 10.14309/ajg.0000000000002175.
    >> Share

  92. REN T, Yu Y, Wang H, Li F, et al
    Maternal Inflammatory Bowel Disease During Pregnancy and Infectious Disease in Offspring Younger Than 5 Years: A Population-Based Cohort Study.
    Am J Gastroenterol. 2023 Jan 26. doi: 10.14309/ajg.0000000000002179.
    >> Share

  93. SUN Y, Yuan S, Chen X, Sun J, et al
    The Contribution of Genetic Risk and Lifestyle Factors in the Development of Adult-Onset Inflammatory Bowel Disease: A Prospective Cohort Study.
    Am J Gastroenterol. 2023 Jan 26. doi: 10.14309/ajg.0000000000002180.
    >> Share

  94. LE COSQUER G, Celerier B, Laharie D
    A Rare Cause of Colonic Obstruction in Inflammatory Bowel Disease.
    Am J Gastroenterol. 2023 Jan 23. doi: 10.14309/ajg.0000000000002116.
    >> Share

  95. ANDERSON J, Frost S, Keyashian K, Modiano N, et al
    Pentosan Polysulfate-Associated Dysplasia in Patients With Inflammatory Bowel Disease: A Case Series.
    Am J Gastroenterol. 2023 Jan 23. doi: 10.14309/ajg.0000000000002137.
    >> Share

  96. LARSEN L, Sandri AK, Fallingborg J, Jacobsen BA, et al
    Has the incidence of inflammatory bowel disease peaked? Evidence from the population-based NorDIBD Cohort 1978-2020.
    Am J Gastroenterol. 2023 Jan 13. doi: 10.14309/ajg.0000000000002187.
    >> Share

  97. SEISHIMA R, Okabayashi K, Ikeuchi H, Uchino M, et al
    Effect of Biologics on the Risk of Advanced-Stage Inflammatory Bowel Disease-Associated Intestinal Cancer: A Nationwide Study.
    Am J Gastroenterol. 2023 Jan 9. doi: 10.14309/ajg.0000000000002149.
    >> Share

  98. HEUTHORST L, Harbech H, Snijder HJ, Mookhoek A, et al
    Increased Proportion of Colorectal Cancer in Patients With Ulcerative Colitis Undergoing Surgery in the Netherlands.
    Am J Gastroenterol. 2023 Jan 6. doi: 10.14309/ajg.0000000000002099.
    >> Share

  99. CHEIFETZ AS, Vande Casteele N, Wang Z, Dubinsky MC, et al
    Higher Postinduction Infliximab Concentrations Are Associated With Favorable Clinical Outcomes in Pediatric Crohn's Disease: A Post Hoc Analysis of the REACH Trial.
    Am J Gastroenterol. 2023 Jan 5. doi: 10.14309/ajg.0000000000002096.
    >> Share

  100. TSE CS, Singh S, Valasek MA, Neill J, et al
    Prevalence and Correlations of Gastrointestinal Symptoms With Endoscopic and Histologic Mucosal Healing in Crohn's Disease.
    Am J Gastroenterol. 2023 Jan 5. doi: 10.14309/ajg.0000000000002122.
    >> Share

  101. NARULA N, Wong ECL, Marshall JK, Jairath V, et al
    Long-Term Outcomes of Early vs Delayed Responders to Vedolizumab and Adalimumab: A Post Hoc Analysis of the VARSITY Study.
    Am J Gastroenterol. 2023;118:121-128.
    >> Share

    December 2022
  102. AXELRAD JE, Cross RK
    Surveillance for colorectal neoplasia in inflammatory bowel disease: When to stop.
    Am J Gastroenterol. 2022 Dec 29. doi: 10.14309/ajg.0000000000002168.
    >> Share

  103. TAKENAKA K, Kitazume Y, Kawamoto A, Fujii T, et al
    Serum Leucine-Rich alpha2 Glycoprotein: A Novel Biomarker for Transmural Inflammation in Crohn's Disease.
    Am J Gastroenterol. 2022 Dec 27. doi: 10.14309/ajg.0000000000002127.
    >> Share

  104. UKASHI O, Kopylov U, Ungar B, Haj-Natour O, et al
    Patency capsule: A novel independent predictor for long-term outcomes among patients with quiescent Crohn's disease.
    Am J Gastroenterol. 2022 Dec 23. doi: 10.14309/ajg.0000000000002118.
    >> Share

  105. ACOSTA MB, Fernandez-Clotet A, Mesonero F, Garcia-Alonso FJ, et al
    Long-term outcomes of biological therapy in Crohn's disease complicated with internal fistulizing disease: BIOSCOPE study from GETECCU.
    Am J Gastroenterol. 2022 Dec 14. doi: 10.14309/ajg.0000000000002152.
    >> Share

  106. CHAPARRO M, Acosta D, Rodriguez C, Mesonero F, et al
    Real-world evidence of tofacinitib in ulcerative colitis: short and long-term effectiveness and safety.
    Am J Gastroenterol. 2022 Dec 14. doi: 10.14309/ajg.0000000000002145.
    >> Share

  107. MA C, Panaccione R, Xiao Y, Khandelwal Y, et al
    REMIT-UC: Real World Effectiveness and Safety of Tofacitinib for Moderate-to-Severely Active Ulcerative Colitis.
    Am J Gastroenterol. 2022 Dec 8. doi: 10.14309/ajg.0000000000002129.
    >> Share

  108. BERENBLUM TOBI C
    Principles for Assessing Quality of Life in Patients With Crohn's Disease.
    Am J Gastroenterol. 2022;117:1952-1953.
    >> Share

  109. SHAFI MA
    Continuing Medical Education Questions: December 2022.
    Am J Gastroenterol. 2022;117:1910.
    >> Share

    November 2022
  110. KAPPELMAN MD, Adimadhyam S, Hou L, Wolfe AE, et al
    Real-World Evidence Comparing Vedolizumab and Ustekinumab in Antitumor Necrosis Factor-Experienced Patients With Crohn's Disease.
    Am J Gastroenterol. 2022 Nov 23. doi: 10.14309/ajg.0000000000002068.
    >> Share

  111. KHAN N, Mahmud N
    COVID-19 Vaccine Effectiveness Against the Omicron Variant in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease.
    Am J Gastroenterol. 2022 Nov 23. doi: 10.14309/ajg.0000000000002071.
    >> Share

  112. VARMA A, Weinstein J, Seabury J, Rosero S, et al
    Patient-Reported Impact of Symptoms in Crohn's Disease.
    Am J Gastroenterol. 2022 Nov 15. doi: 10.14309/ajg.0000000000001954.
    >> Share

  113. BIRCH RJ, Burr N, Subramanian V, Tiernan JP, et al
    Inflammatory Bowel Disease-Associated Colorectal Cancer Epidemiology and Outcomes: An English Population-Based Study.
    Am J Gastroenterol. 2022;117:1858-1870.
    >> Share

  114. DUNLEAVY K, Fogwe D, Forde G, Ho M, et al
    A Rare Complication: Postoperative Pyoderma Gangrenosum in Segmental Colitis Associated With Diverticulosis.
    Am J Gastroenterol. 2022;117:1734.
    >> Share

  115. CHENG D, Kochar B, Cai T, Ritchie CS, et al
    Comorbidity Influences the Comparative Safety of Biologic Therapy in Older Adults With Inflammatory Bowel Diseases.
    Am J Gastroenterol. 2022;117:1845-1850.
    >> Share

    October 2022
  116. BERNSTEIN CN, Fisk JD, Walld R, Bolton JM, et al
    Use of Benzodiazepines and Z-Drugs in Inflammatory Bowel Disease.
    Am J Gastroenterol. 2022 Oct 27. pii: 00000434-990000000-00474.
    >> Share

  117. FAIRBRASS KM, Guthrie EA, Black CJ, Selinger CP, et al
    Characteristics and Impact of Anxiety and Depression Trajectories in Inflammatory Bowel Disease.: Anxiety and Depression Trajectories in IBD.
    Am J Gastroenterol. 2022 Oct 12. pii: 00000434-990000000-00552.
    >> Share

  118. EGBERG MD, Zhang X, Smitherman AB, Kappelman MD, et al
    LOW RISK OF LYMPHOMA IN PEDIATRIC PATIENTS TREATED FOR INFLAMMATORY BOWEL DISEASE.
    Am J Gastroenterol. 2022 Oct 10. pii: 00000434-990000000-00543.
    >> Share

  119. DONG J, Ladonne M, Feuerstein JD
    Medicare Patients Face High Out-of-Pocket Costs for Specialty Inflammatory Bowel Disease Medications.
    Am J Gastroenterol. 2022 Oct 10. pii: 00000434-990000000-00549.
    >> Share

  120. INAMDAR S
    Continuing Medical Education Questions: October 2022.
    Am J Gastroenterol. 2022;117:1564.
    >> Share

  121. SHMIDT E, Dubinsky MC
    Inflammatory Bowel Disease and Pregnancy.
    Am J Gastroenterol. 2022;117.
    >> Share

  122. GU P, Luo J, Kim J, Paul P, et al
    Effect of Obesity on Risk of Hospitalization, Surgery, and Serious Infection in Biologic-Treated Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study.
    Am J Gastroenterol. 2022;117:1639-1647.
    >> Share

    September 2022
  123. KASTL A, Weaver KN, Zhang X, Strople JA, et al
    Humoral Immune Response and Safety of SARS-CoV-2 Vaccination in Pediatric Inflammatory Bowel Disease.
    Am J Gastroenterol. 2022 Sep 16. pii: 00000434-990000000-00507.
    >> Share

  124. GUPTA A, Kizza JF, Ananthakrishnan AN
    Histologic activity in an endoscopically normal appearing pouch predicts future risk of pouchitis in patients with ulcerative colitis.
    Am J Gastroenterol. 2022 Sep 16. pii: 00000434-990000000-00511.
    >> Share

  125. DULANEY DT
    Continuing Medical Education Questions: September 2022.
    Am J Gastroenterol. 2022;117:1407.
    >> Share

  126. BOSCHETTI G, Nachury M, Laharie D, Roblin X, et al
    Efficacy and Safety of Infliximab Retreatment in Crohn's Disease: A Multicentre, Prospective, Observational Cohort (REGAIN) Study from the GETAID.
    Am J Gastroenterol. 2022;117:1482-1490.
    >> Share

    August 2022
  127. DANESE S, Ferrante M, Feagan BG, Peyrin-Biroulet L, et al
    Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial.
    Am J Gastroenterol. 2022 Aug 23. pii: 00000434-990000000-00486.
    >> Share

  128. COHEN-MEKELBURG S, Van T, Wallace B, Berinstein J, et al
    The association between non-steroidal anti-inflammatory drug use and inflammatory bowel disease exacerbations: a true association or residual bias?
    Am J Gastroenterol. 2022 Aug 12. pii: 00000434-990000000-00457.
    >> Share

  129. AGRAWAL M, Allin KH, Iversen AT, Mehandru S, et al
    Early life mebendazole exposure increases the risk of adult-onset ulcerative colitis: a population-based cohort study.
    Am J Gastroenterol. 2022 Aug 12. pii: 00000434-990000000-00466.
    >> Share

  130. VAN DEEN WK, Simpson M, Dupuy TP, Khalil C, et al
    Social Media for the Dissemination of Educational Videos About Inflammatory Bowel Diseases.
    Am J Gastroenterol. 2022;117:1320-1323.
    >> Share

  131. ONALI S, Pugliese D, Caprioli FA, Orlando A, et al
    An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors.
    Am J Gastroenterol. 2022;117:1279-1287.
    >> Share

    July 2022
  132. BESSISSOW T, Kron CM, Marcus V, Lemieux C, et al
    Impact of Endoscopic and Histologic Activity on Disease Relapse in Ulcerative Colitis.
    Am J Gastroenterol. 2022 Jul 21. pii: 00000434-990000000-00439.
    >> Share

  133. LO B, Liu Z, Bendtsen F, Igel C, et al
    High accuracy in classifying endoscopic severity in ulcerative colitis using convolutional neural network.
    Am J Gastroenterol. 2022 Jul 15. pii: 00000434-990000000-00434.
    >> Share

  134. ISAACS K, Kane S
    Doctor, What Is the Best Crohn's Therapy?
    Am J Gastroenterol. 2022;117:1041-1043.
    >> Share

  135. JAIN A, Bricker J, Kappelman MD, Dotson JL, et al
    Overweight and Obese Status Is Not Associated With Disease Activity for Children and Adolescents With Newly Diagnosed Inflammatory Bowel Disease.
    Am J Gastroenterol. 2022;117:1146-1153.
    >> Share

  136. NARULA N, Wong ECL, Dulai PS, Marshall JK, et al
    Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease.
    Am J Gastroenterol. 2022;117:1106-1117.
    >> Share

    June 2022
  137. ALMARIO CV, van Deen WK, Chen M, Gale R, et al
    Interactive Inflammatory Bowel Disease Biologics Decision Aid Does Not Improve Patient Outcomes Over Static Education: Results from a Randomized Trial.
    Am J Gastroenterol. 2022 Jun 10. pii: 00000434-990000000-00406.
    >> Share

    May 2022
  138. MARILD K, Soderling J, Lebwohl B, Green PH, et al
    ASSOCIATION OF CELIAC DISEASE AND INFLAMMATORY BOWEL DISEASE: A NATIONWIDE REGISTER-BASED COHORT STUDY.
    Am J Gastroenterol. 2022 May 25. pii: 00000434-990000000-00380.
    >> Share

    April 2022
  139. KAPLAN HC, Opipari-Arrigan L, Yang J, Schmid CH, et al
    Personalized Research on Diet in Ulcerative Colitis and Crohn's Disease (PRODUCE): A Series of N-of-1 Diet Trials.
    Am J Gastroenterol. 2022 Apr 20. pii: 00000434-990000000-00348.
    >> Share

  140. LUTZ M, Hayney MS, Caldera F
    We should not forget about patients with inflammatory bowel disease who received a COVID-19 viral vector vaccine.
    Am J Gastroenterol. 2022 Apr 15. pii: 00000434-990000000-00337.
    >> Share

  141. DULAI PS, Rai V, Raffals LE, Lukin D, et al
    Recommendations on the appropriate management of steroids and discharge planning during and after hospital admission for moderate-severe ulcerative colitis: results of a RAND appropriateness panel.
    Am J Gastroenterol. 2022 Apr 13. pii: 00000434-990000000-00329.
    >> Share

  142. SASSINE S, Djani L, Cambron-Asselin C, Savoie M, et al
    Risk Factors of Clinical Relapses in Pediatric Luminal Crohn's Disease: A Retrospective Cohort Study.
    Am J Gastroenterol. 2022;117:637-646.
    >> Share

    March 2022
  143. ROLAK S, Caldera F
    The current knowns and unknowns of COVID-19 vaccine induced immunity in patients with inflammatory bowel disease.
    Am J Gastroenterol. 2022 Mar 15. pii: 00000434-990000000-00282.
    >> Share

  144. WINTER RW, Friedman S, Nielsen J, Kjeldsen J, et al
    Infliximab Is Not Associated With a General Long-Term Weight Gain in Patients With Inflammatory Bowel Disease: A Nationwide Study.
    Am J Gastroenterol. 2022 Mar 14. pii: 00000434-990000000-00278.
    >> Share

  145. KAPPELMAN MD, Weaver KN, Zhang X, Dai X, et al
    Factors Affecting Initial Humoral Immune Response to SARS-CoV-2 Vaccines Among Patients With Inflammatory Bowel Diseases.
    Am J Gastroenterol. 2022;117:462-469.
    >> Share

    February 2022
  146. SNINSKY JA, Barnes EL, Zhang X, Long MD, et al
    Urgency and its association with quality of life and clinical outcomes in ulcerative colitis patients.
    Am J Gastroenterol. 2022 Feb 15. pii: 00000434-990000000-00253.
    >> Share

    January 2022
  147. TSIPOTIS E, Frey S, Connolly C, Werbel WA, et al
    Antibody Response Three Months after Two-Dose SARS-CoV-2 mRNA Vaccination in patients with Inflammatory Bowel Disease.
    Am J Gastroenterol. 2022 Jan 29. pii: 00000434-990000000-00231.
    >> Share

  148. HAMADA K, Mankawa N, Yamamoto S
    May-Thurner syndrome in a patient with ulcerative colitis complicated by coronavirus disease 2019.
    Am J Gastroenterol. 2022 Jan 29. pii: 00000434-990000000-00233.
    >> Share

  149. GARRIDO I, Lopes S, Andrade P, Real AC, et al
    Immune Response Induced by SARS-CoV-2 Vaccines in Patients With Inflammatory Bowel Disease Under Biologic Therapy.
    Am J Gastroenterol. 2022 Jan 24. pii: 00000434-990000000-00217.
    >> Share

    December 2021
  150. MOLLY S, Margaret M, Erin F
    P076 The Role of Dual Biologic Therapy in Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021;116.
    >> Share

  151. JARED S, Edward B, Xian Z, Millie L, et al
    P075 Urgency and its Association with Quality of Life and Clinical Outcomes in Ulcerative Colitis Patients.
    Am J Gastroenterol. 2021;116.
    >> Share

  152. RAHUL D, Jennifer M, Hannah G, Jessica A, et al
    P074 Comparative Risk of Clostridioides Difficile Infection in Vedolizumab vs anti-TNFa Agents in Biologic-Naive Patients With Ulcerative Colitis.
    Am J Gastroenterol. 2021;116.
    >> Share

  153. BENJAMIN S, Kristine P, Kevin T, James M, et al
    P072 Non-invasive Vagal Nerve Stimulation to Treat Crohn Disease and Ulcerative Colitis in Children and Young Adults: A Proof-of-Concept Clinical Trial.
    Am J Gastroenterol. 2021;116.
    >> Share

  154. JOSE RL, Jesus LG, Tomas CE, Korely TF, et al
    P063 Prevalence in the Use of Complementary/Alternative Medicine in Patients With Inflammatory Bowel Disease from Centro Medico Nacional 20 de Noviembre.
    Am J Gastroenterol. 2021;116.
    >> Share

  155. KORELY TF, Jesus LG, Tomas CE, Rebeca PC, et al
    P061 Impact of Inflammatory Bowel Disease on sleep quality in a Mexican population attended in a referral center.
    Am J Gastroenterol. 2021;116.
    >> Share

  156. VIVIANA PI, Jaiber G, Cristian F, Diego J, et al
    P060 Screening Criteria of Inflammatory Bowel Disease: Application in Colombian Patients With Spondyloarthritis.
    Am J Gastroenterol. 2021;116.
    >> Share

  157. JULTON TC, Lauren S, Mouhammed S, Adil M, et al
    P058 Impact of Inflammatory Bowel Disease Treatment and Risk of Covid-19 Infection after Full Immunization: A Nationwide Analysis.
    Am J Gastroenterol. 2021;116.
    >> Share

  158. CARLOS PA, Tomas CE, Jesus LG, Korely TF, et al
    P057 How Distance Between Residence and Treatment Center Impact the Outcome of Patients With Inflammatory Bowel Disease at CMN 20.
    Am J Gastroenterol. 2021;116.
    >> Share

  159. VIVIANA PI, Juan FO, Pablo G, Consuelo RS, et al
    P056 Real life experience with the use of tofacitinib in ulcerative colitis in Colombia: case series.
    Am J Gastroenterol. 2021;116.
    >> Share

  160. SANG TC, Sarah A, Yousef E, Joshua T, et al
    P055 Sociodemographic Differences in Fecal Enteropathogen Testing Patterns in Adults Hospitalized for Inflammatory Bowel Disease Flares.
    Am J Gastroenterol. 2021;116.
    >> Share

  161. MIKAELL F, Ligia S, Adriana A, Roberto KJ, et al
    P052 National Registration of Patients With Inflammatory Bowel Disease in Brazil on Behalf of GEDIIB.
    Am J Gastroenterol. 2021;116.
    >> Share

  162. MARTA F, Tiago LC, Vitor MS, Catia A, et al
    P051 Identifying High-Risk Patients With Acute Severe Ulcerative Colitis: Is the ACE Index Useful?
    Am J Gastroenterol. 2021;116.
    >> Share

  163. VIVIANA PI, Katherin C, Julio A, Maria B, et al
    P050 Oral Inflammatory Changes Associated With Inflammatory Bowel Disease in Spondyloarthritis Associated With Early Endoscopic Findings.
    Am J Gastroenterol. 2021;116.
    >> Share

  164. DANIEL S, Marina L, Ana Carolina O, Rodrigo B, et al
    P049 Investigation of Liver Diseases by Ultrasound in Patients With Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021;116.
    >> Share

  165. MARINA L, Daniel S, Ana Carolina O, Rodrigo B, et al
    P045 Prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with inflammatory bowel disease (IBD) in a Brazilian public healthcare clinic.
    Am J Gastroenterol. 2021;116.
    >> Share

  166. QIAN C, Myrlene S, Nurgul B, Lilla DS, et al
    P043 Resource Utilization and Productivity Loss among Patients with Inflammatory Bowel Disease in Sweden: A Longitudinal Nationwide Population-based Study.
    Am J Gastroenterol. 2021;116.
    >> Share

  167. MILLIE L, Raymond C, Jonathan C, Marc P, et al
    P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis.
    Am J Gastroenterol. 2021;116.
    >> Share

  168. JEAN-FREDERIC C, Geert D, Peter I, AnnKatrin P, et al
    P037 Effect of Ozanimod Treatment and Discontinuation on Absolute Lymphocyte Count in Moderate-to-Severe Ulcerative Colitis: Results from a Phase 3 Trial.
    Am J Gastroenterol. 2021;116.
    >> Share

  169. DAVID H, Millie L, Douglas W, Stephen H, et al
    P035 Ozanimod for Moderate-to-Severe Ulcerative Colitis: North American Population Results During Induction and Maintenance in the Phase 3 True North Study.
    Am J Gastroenterol. 2021;116.
    >> Share

  170. BRUCE S, Marc P, Michael S, AnnKatrin P, et al
    P031 Impact of Prior Biologic Exposure on Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study.
    Am J Gastroenterol. 2021;116.
    >> Share

  171. DAVID R, Remo P, Alison PB, Cem K, et al
    P028 Communicating Needs and Features of IBD Experiences (CONFIDE) Survey: Patient and Healthcare Professional Perspectives on Experience of Ulcerative Colitis Symptoms.
    Am J Gastroenterol. 2021;116.
    >> Share

  172. APAAR D, Khushboo G, Jayesh R, Shesh R, et al
    P027 Brain Fog in Patients With Inflammatory Bowel Disease, and Association With Use of Probiotics.
    Am J Gastroenterol. 2021;116.
    >> Share

  173. ADAM S, Nicole L, Heba I, Harini N, et al
    P026 Inflammatory Bowel Disease (IBD) Related Outcomes in Patients Diagnosed With COVID-19.
    Am J Gastroenterol. 2021;116.
    >> Share

  174. SIGRID Y, Scott S, Shannon C
    P024 Anorectal Manometry in Patients with Fecal Incontinence After Ileal Pouch-Anal Anastomosis for Inflammatory Bowel Disease: A Cohort Study.
    Am J Gastroenterol. 2021;116.
    >> Share

  175. KEVIN C, Sandra K, Noll R
    P023 Parental Distress in Pediatric Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021;116.
    >> Share

  176. VARUN J, Brian B, Esteban F
    P022 Biologic Therapy and Therapeutic Drug Monitoring in Patients With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.
    Am J Gastroenterol. 2021;116.
    >> Share

  177. VITOR MS, Tiago LC, Marta F, Tiago CG, et al
    P020 Proton Pump Inhibitor Therapy: Providing "Acid" Outcomes in Patients With Inflammatory Bowel Disease Under Infliximab Treatment.
    Am J Gastroenterol. 2021;116.
    >> Share

  178. IANA G, Randall J, Marc P
    P019 Not All Fecal Calprotectin is Specific for Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021;116.
    >> Share

  179. MARIYA Z, Oleg K, Karina N
    P017 Increased Level of Immunoglobulin G in the Development of Adverse Reactions in Patients With Ulcerative Colitis.
    Am J Gastroenterol. 2021;116.
    >> Share

  180. RICHARD WY
    P011 Prevalence of Cannabis Use Disorder in Inflammatory Bowel Disease Hospitalizations in the United States and Effect on Length of Stay.
    Am J Gastroenterol. 2021;116.
    >> Share

  181. HARTMAN B, Diana H, Casey C
    P009 Assessing the Status Quo: Ulcerative Colitis Monitoring in a Community GI Practice.
    Am J Gastroenterol. 2021;116.
    >> Share

  182. OLEG K, Sergey K, Anna K, Albina L, et al
    P006 The Relationship of Histological Remission With the Duration of the Anamnesis Ulcerative Colitis.
    Am J Gastroenterol. 2021;116.
    >> Share

  183. OLEG K, Anna K, Albina L, Anait B, et al
    P004 Steroid-Free Remission in Patients With Ulcerative Colitis Receiving Tofacitinib in Real Clinical Practice.
    Am J Gastroenterol. 2021;116.
    >> Share

  184. HUI C, Tian F, Lintao D, Xuejie C, et al
    P003 Meat Consumption and All-Cause Mortality in 5763 Inflammatory Bowel Disease Patients: A Prospective Cohort Study.
    Am J Gastroenterol. 2021;116.
    >> Share

  185. STONE M, Morrison M, Forster E
    P076 The Role of Dual Biologic Therapy in Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021;116.
    >> Share

  186. SNINSKY J, Barnes E, Zhang X, Long M, et al
    P075 Urgency and its Association with Quality of Life and Clinical Outcomes in Ulcerative Colitis Patients.
    Am J Gastroenterol. 2021;116.
    >> Share

  187. DALAL R, Mitri J, Goodrick H, Allegretti J, et al
    P074 Comparative Risk of Clostridioides Difficile Infection in Vedolizumab vs anti-TNFa Agents in Biologic-Naive Patients With Ulcerative Colitis.
    Am J Gastroenterol. 2021;116.
    >> Share

  188. SAHN B, Pascuma K, Tracey K, Markowitz J, et al
    P072 Non-invasive Vagal Nerve Stimulation to Treat Crohn Disease and Ulcerative Colitis in Children and Young Adults: A Proof-of-Concept Clinical Trial.
    Am J Gastroenterol. 2021;116.
    >> Share

  189. ROMERO LJ, Gomez JL, Espinosa TC, Trujillo de la Fuente K, et al
    P063 Prevalence in the Use of Complementary/Alternative Medicine in Patients With Inflammatory Bowel Disease from Centro Medico Nacional 20 de Noviembre.
    Am J Gastroenterol. 2021;116.
    >> Share

  190. TRUJILLO DE LA FUENTE K, Lopez Gomez J, Cortes Espinosa T, Perez-Cabeza de Vaca R, et al
    P061 Impact of Inflammatory Bowel Disease on sleep quality in a Mexican population attended in a referral center.
    Am J Gastroenterol. 2021;116.
    >> Share

  191. PARRA IZQUIERDO V, Gutierrez J, Florez C, Jaimes D, et al
    P060 Screening Criteria of Inflammatory Bowel Disease: Application in Colombian Patients With Spondyloarthritis.
    Am J Gastroenterol. 2021;116.
    >> Share

  192. PAREDES AMENABAR C, Cortes Espinosa T, Lopez Gomez J, Trujillo de la Fuente K, et al
    P057 How Distance Between Residence and Treatment Center Impact the Outcome of Patients With Inflammatory Bowel Disease at CMN 20.
    Am J Gastroenterol. 2021;116.
    >> Share

  193. PARRA IZQUIERDO V, Frias-Ordonez J, Galindo P, Romero-Sanchez C, et al
    P056 Real life experience with the use of tofacitinib in ulcerative colitis in Colombia: case series.
    Am J Gastroenterol. 2021;116.
    >> Share

  194. TSE CS, Andrea S, Elfanagely Y, Tanzer J, et al
    P055 Sociodemographic Differences in Fecal Enteropathogen Testing Patterns in Adults Hospitalized for Inflammatory Bowel Disease Flares.
    Am J Gastroenterol. 2021;116.
    >> Share

  195. FARIA M, Sassaki L, Andrade A, Kaiser Junior R, et al
    P052 National Registration of Patients With Inflammatory Bowel Disease in Brazil on Behalf of GEDIIB.
    Am J Gastroenterol. 2021;116.
    >> Share

  196. FREITAS M, Capela TL, Macedo Silva V, Arieira C, et al
    P051 Identifying High-Risk Patients With Acute Severe Ulcerative Colitis: Is the ACE Index Useful?
    Am J Gastroenterol. 2021;116.
    >> Share

  197. PARRA IZQUIERDO V, Chumacero K, Alvarado J, Buenahora M, et al
    P050 Oral Inflammatory Changes Associated With Inflammatory Bowel Disease in Spondyloarthritis Associated With Early Endoscopic Findings.
    Am J Gastroenterol. 2021;116.
    >> Share

  198. SHINTAKU D, Lopes M, de Oliveira AC, Beraldo R, et al
    P049 Investigation of Liver Diseases by Ultrasound in Patients With Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021;116.
    >> Share

  199. LOPES M, Shintaku D, de Oliveira AC, Beraldo R, et al
    P045 Prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with inflammatory bowel disease (IBD) in a Brazilian public healthcare clinic.
    Am J Gastroenterol. 2021;116.
    >> Share

  200. CAI Q, Sanon M, Batyrbekova N, Di Scala L, et al
    P043 Resource Utilization and Productivity Loss among Patients with Inflammatory Bowel Disease in Sweden: A Longitudinal Nationwide Population-based Study.
    Am J Gastroenterol. 2021;116.
    >> Share

  201. LONG M, Cross R, Calkwood J, Pondel M, et al
    P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis.
    Am J Gastroenterol. 2021;116.
    >> Share

  202. COLOMBEL JF, D'Haens G, Irving P, Petersen A, et al
    P037 Effect of Ozanimod Treatment and Discontinuation on Absolute Lymphocyte Count in Moderate-to-Severe Ulcerative Colitis: Results from a Phase 3 Trial.
    Am J Gastroenterol. 2021;116.
    >> Share

  203. HUDESMAN D, Long M, Wolf D, Hanauer S, et al
    P035 Ozanimod for Moderate-to-Severe Ulcerative Colitis: North American Population Results During Induction and Maintenance in the Phase 3 True North Study.
    Am J Gastroenterol. 2021;116.
    >> Share

  204. SANDS B, Pondel M, Silver M, Petersen A, et al
    P031 Impact of Prior Biologic Exposure on Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study.
    Am J Gastroenterol. 2021;116.
    >> Share

  205. RUBIN D, Panaccione R, Potts Bleakman A, Kayhan C, et al
    P028 Communicating Needs and Features of IBD Experiences (CONFIDE) Survey: Patient and Healthcare Professional Perspectives on Experience of Ulcerative Colitis Symptoms.
    Am J Gastroenterol. 2021;116.
    >> Share

  206. DADLANI A, Gala K, Rai J, Rai S, et al
    P027 Brain Fog in Patients With Inflammatory Bowel Disease, and Association With Use of Probiotics.
    Am J Gastroenterol. 2021;116.
    >> Share

  207. YOUNG S, Smukalla S, Chang S
    P024 Anorectal Manometry in Patients with Fecal Incontinence After Ileal Pouch-Anal Anastomosis for Inflammatory Bowel Disease: A Cohort Study.
    Am J Gastroenterol. 2021;116.
    >> Share

  208. CESA K, Kim S, Robert N
    P023 Parental Distress in Pediatric Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021;116.
    >> Share

  209. JAIN V, Behm B, Figueroa E
    P022 Biologic Therapy and Therapeutic Drug Monitoring in Patients With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.
    Am J Gastroenterol. 2021;116.
    >> Share

  210. MACEDO SILVA V, Lima Capela T, Freitas M, Curdia Goncalves T, et al
    P020 Proton Pump Inhibitor Therapy: Providing "Acid" Outcomes in Patients With Inflammatory Bowel Disease Under Infliximab Treatment.
    Am J Gastroenterol. 2021;116.
    >> Share

  211. GUEORGUIEVA I, Jacobs R, Piper M
    P019 Not All Fecal Calprotectin is Specific for Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021;116.
    >> Share

  212. ZVYAGLOVA M, Knyazev O, Noscova K
    P017 Increased Level of Immunoglobulin G in the Development of Adverse Reactions in Patients With Ulcerative Colitis.
    Am J Gastroenterol. 2021;116.
    >> Share

  213. WANG YR
    P011 Prevalence of Cannabis Use Disorder in Inflammatory Bowel Disease Hospitalizations in the United States and Effect on Length of Stay.
    Am J Gastroenterol. 2021;116.
    >> Share

  214. BRUNT H, Hamer D, Chapman C
    P009 Assessing the Status Quo: Ulcerative Colitis Monitoring in a Community GI Practice.
    Am J Gastroenterol. 2021;116.
    >> Share

  215. KNYAZEV O, Khomeriki S, Kagramanova A, Lishchinskaya A, et al
    P006 The Relationship of Histological Remission With the Duration of the Anamnesis Ulcerative Colitis.
    Am J Gastroenterol. 2021;116.
    >> Share

  216. KNYAZEV O, Kagramanova A, Lishchinskaya A, Babayan A, et al
    P004 Steroid-Free Remission in Patients With Ulcerative Colitis Receiving Tofacitinib in Real Clinical Practice.
    Am J Gastroenterol. 2021;116.
    >> Share

  217. CHEN H, Fu T, Dan L, Chen X, et al
    P003 Meat Consumption and All-Cause Mortality in 5763 Inflammatory Bowel Disease Patients: A Prospective Cohort Study.
    Am J Gastroenterol. 2021;116.
    >> Share

  218. DAI C, Jiang M, Huang YH
    The Association Between Serum Infliximab Concentrations and Clinical Outcomes in Fistulizing Crohn's Disease.
    Am J Gastroenterol. 2021;116:2481-2482.
    >> Share

    November 2021
  219. MELMED GY, Oliver B, Hou JK, Lum D, et al
    Quality of Care Program Reduces Unplanned Health Care Utilization in Patients With Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021 Nov 19. pii: 00000434-990000000-00153.
    >> Share

  220. CALDERA F, Knutson KL, Saha S, Wald A, et al
    Humoral Immunogenicity of mRNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease and Healthy Controls.
    Am J Gastroenterol. 2021 Nov 18. pii: 00000434-990000000-00148.
    >> Share

  221. BRUNT H, Chapman JC
    The Inflammatory Bowel Disease-Focused Primary Care Provider: An Addition to the IBD Specialty Medical Home.
    Am J Gastroenterol. 2021 Nov 17. pii: 00000434-990000000-00144.
    >> Share

  222. NGUYEN NH, Martinez I, Atreja A, Sitapati AM, et al
    Digital Health Technologies for Remote Monitoring and Management of Inflammatory Bowel Disease: A Systematic Review.
    Am J Gastroenterol. 2021 Nov 9. pii: 00000434-990000000-00141.
    >> Share

  223. ALMARIO CV, Kogan L, van Deen WK, Scott FI, et al
    Health Economic Impact of a Multicenter Quality-of-Care Initiative for Reducing Unplanned Healthcare Utilization Among Patients With Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021 Nov 3. pii: 00000434-990000000-00133.
    >> Share

  224. CHO JM, Loftus EV Jr, Bruining DH, Chedid VG, et al
    Vulvar Crohn's Disease: Clinical Features and Outcomes.
    Am J Gastroenterol. 2021;116:2296-2299.
    >> Share

    October 2021
  225. LAUBE R, Tran Y, Paramsothy S, Leong RW, et al
    Assisted Reproductive Technology in Crohn's Disease and Ulcerative Colitis: A Systematic Review and Meta-Analysis.
    Am J Gastroenterol. 2021 Oct 25. pii: 00000434-990000000-00131.
    >> Share

  226. THAKUR K, Barrett TA
    Social Determinants of Health in Inflammatory Bowel Diseases: Barriers and Opportunities.
    Am J Gastroenterol. 2021;116:2146.
    >> Share

  227. ASHHAB AA, Lee M, Melmed GY
    Extensive Upper Gastrointestinal Fistulization in Crohn's Disease, an Uncommon Cause for a Common Presentation.
    Am J Gastroenterol. 2021;116:1978.
    >> Share

    September 2021
  228. BATTAT R, Long MD
    Is Proactive Therapeutic Drug Monitoring Ready for the Spotlight in Inflammatory Bowel Disease? Follow the Data.
    Am J Gastroenterol. 2021 Sep 13. pii: 00000434-990000000-00100.
    >> Share

    August 2021
  229. SANGHA M, Roitman I, Sultan K, Swaminath A, et al
    SARS-CoV-2 Immunization in Patients With Inflammatory Bowel Disease May Result in Disease Flares.
    Am J Gastroenterol. 2021 Aug 18. pii: 00000434-990000000-00081.
    >> Share

  230. CHEIFETZ AS, Abreu MT, Afif W, Cross RK, et al
    A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021 Aug 13. pii: 00000434-990000000-00067.
    >> Share

  231. RICCIUTO A, Carman N, Benchimol EI, Siddiqui I, et al
    Prospective Evaluation of Endoscopic and Histologic Indices in Pediatric Ulcerative Colitis Using Centralized Review.
    Am J Gastroenterol. 2021 Aug 13. pii: 00000434-990000000-00066.
    >> Share

  232. DULAI PS, Jairath V, Narula N, Wong E, et al
    A Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Crohn's Disease.
    Am J Gastroenterol. 2021;116:1709-1719.
    >> Share

    July 2021
  233. HARRISON N, Humes R, Singla M
    Skip, Stop, Switch, and Spare: Steroid Therapy in Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021 Jul 19. pii: 00000434-990000000-00049.
    >> Share

  234. SCHUMANN M, Sonnenberg E, Siegmund B, Meier K, et al
    A 39-Year-Old Man With Crohn's Disease and a Unclear Rash on His Left Cheek.
    Am J Gastroenterol. 2021;116:1374.
    >> Share

    June 2021
  235. ABDALLA MI, Levesque BG
    Progress in Corticosteroid Use in the Era of Biologics With Room for Improvement.
    Am J Gastroenterol. 2021;116:1187-1188.
    >> Share

  236. TARGOWNIK LE, Bernstein CN, Benchimol EI, Kaplan GG, et al
    Trends in Corticosteroid Use During the Era of Biologic Therapy: A Population-Based Analysis.
    Am J Gastroenterol. 2021;116:1284-1293.
    >> Share

    May 2021
  237. DE GIORGI V, Trane L, Silvestri F, Venturi F, et al
    Pyodermatitis-Pyostomatitis Vegetans in Active Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021 May 31. pii: 00000434-900000000-98762.
    >> Share

  238. BOTWIN GJ, Li D, Figueiredo J, Cheng S, et al
    Adverse Events Following SARS-CoV-2 mRNA Vaccination: Among Patients with Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021 May 25. pii: 00000434-900000000-98766.
    >> Share

  239. TEICH N, Stallmach A, Bruns T
    Greenspace in Childhood: A New Avenue to Prevent Inflammatory Bowel Disease?
    Am J Gastroenterol. 2021 May 7. pii: 00000434-900000000-98784.
    >> Share

  240. TANG J, Huang Z, Guo H, Ding N, et al
    Online Video Clinic Satisfies the Medical Requirements of Patients with IBD During the COVID-19 Outbreak.
    Am J Gastroenterol. 2021;116:1087.
    >> Share

  241. PAPAMICHAEL K, Vande Casteele N, Jeyarajah J, Jairath V, et al
    Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn's Disease: An ACCENT-II Post Hoc Analysis.
    Am J Gastroenterol. 2021;116:1007-1014.
    >> Share

    April 2021
  242. KHAN N, Patel D, Xie D, Pernes T, et al
    Are Patients With Inflammatory Bowel Disease at an Increased Risk of Developing SARS-CoV-2 than Patients Without Inflammatory Bowel Disease? Results From a Nationwide Veterans' Affairs Cohort Study.
    Am J Gastroenterol. 2021;116:808-810.
    >> Share

  243. KHAN N, Patel D, Trivedi C, Kavani H, et al
    Incidence of Acute Myeloid Leukemia and Myelodysplastic Syndrome in Patients With Inflammatory Bowel Disease and the Impact of Thiopurines on Their Risk.
    Am J Gastroenterol. 2021;116:741-747.
    >> Share

  244. SONNENBERG A
    Do Forgotten Symptoms Need Treatment?
    Am J Gastroenterol. 2021;116:841-842.
    >> Share

  245. HA C
    The Age-Old Conundrum With Thiopurines: Are the Accumulating Risks Greater Than Benefits?
    Am J Gastroenterol. 2021;116:671-672.
    >> Share

    March 2021
  246. BERNSTEIN CN, Nugent Z, Singh H
    Persistently High Rate of Venous Thromboembolic Disease in Inflammatory Bowel Disease: A Population-Based Study.
    Am J Gastroenterol. 2021 Mar 24. pii: 00000434-900000000-98845.
    >> Share

  247. SLATER NR, Loomes DE
    Endoscopic Vacuum-Assisted Wound Closure of a Rectal Perforation in the Setting of Active Ulcerative Colitis.
    Am J Gastroenterol. 2021 Mar 2. pii: 00000434-900000000-98819.
    >> Share

    January 2021
  248. COELHO-PRABHU N, Kane S
    Does Size Really Matter?
    Am J Gastroenterol. 2021;116:84-85.
    >> Share

  249. HAMMOUDI N, Allez M
    Response to Hanzel.
    Am J Gastroenterol. 2021;116:218.
    >> Share

  250. HANZEL J
    A Novel Endoscopic Score for Postoperative Recurrence of Crohn's Disease: More Information Needed.
    Am J Gastroenterol. 2021;116:217-218.
    >> Share

  251. RIVIERE P, D'Haens G, Peyrin-Biroulet L, Baert F, et al
    Location but Not Severity of Endoscopic Lesions Influences Endoscopic Remission Rates in Crohn's Disease: A Post Hoc Analysis of TAILORIX.
    Am J Gastroenterol. 2021;116:134-141.
    >> Share

    December 2020
  252. LACY BE, Pimentel M, Brenner DM, Chey WD, et al
    ACG Clinical Guideline: Management of Irritable Bowel Syndrome.
    Am J Gastroenterol. 2020 Dec 14. doi: 10.14309/ajg.0000000000001036.
    >> Share

  253. KORELITZ BI, Sachar DB, Schneider J
    Full Potential of 6-Mercaptopurine in IBD May Remain Untapped.
    Am J Gastroenterol. 2020;115:2109-2110.
    >> Share

  254. FERNANDA F, Mirella O, Danielle F, Pedro G, et al
    P074 Prevalence and Associated Factors With Non-Adherence to Maintenance Therapy for Ulcerative Colitis in Deep Remission.
    Am J Gastroenterol. 2020;115.
    >> Share

  255. PRADEEP KR, Deloshaan S, Dheeraj S, Hadi M, et al
    P070 Outcomes of Acute Severe Ulcerative Colitis in Older Adults.
    Am J Gastroenterol. 2020;115.
    >> Share

  256. DELOSHAAN S, Pradeep KR, Dheeraj S, Hadi M, et al
    P069 Admission Steroid Use, Serum Albumin and Endoscopic Severity Predict Intravenous Steroid Failure in Patients With Acute Severe Ulcerative Colitis.
    Am J Gastroenterol. 2020;115.
    >> Share

  257. JAQUELINE B, Juliana C, Dos Santos B, Caroline D, et al
    P068 Therapeutic Aspects in Pediatric Inflammatory Bowel Disease - A Multi-Centric Study From Brazil.
    Am J Gastroenterol. 2020;115.
    >> Share

  258. FLAVIA P, Cyrla Z, de Souza H, Jessica M, et al
    P066 Hospitalization and Surgery Rates in Patients With Inflammatory Bowel Disease in Brazil: A Time-Trend Analysis.
    Am J Gastroenterol. 2020;115.
    >> Share

  259. JENNIFER MO, Megan L, Jean A
    P065 Inflammatory Bowel Disease or Bowel Endometriosis? Two Cases of Large Bowel Obstruction.
    Am J Gastroenterol. 2020;115.
    >> Share

  260. JAQUELINE B, Juliana C, Dos Santos Beatriz, Caroline D, et al
    P064 Clinical Aspects of Pediatric Inflammatory Bowel Disease - A Multicentric Study From Brazil.
    Am J Gastroenterol. 2020;115.
    >> Share

  261. FABIANA B, Cesar A, Marcio C, Carolina M, et al
    P061 Prophylaxis of Hepatitis B Reactivation and Inflammatory Bowel Disease: A case report.
    Am J Gastroenterol. 2020;115.
    >> Share

  262. SVETLANA L, Morris G, Vasiliki S
    P056 Power Calculations in Randomised Controlled Trials of Inflammatory Bowel Disease.
    Am J Gastroenterol. 2020;115.
    >> Share

  263. WALAA M, Hisham W, Walid H, Fadi F, et al
    P049 Should the Gallbladder be Empirically Removed at Time of Intestinal Resection in Inflammatory Bowel Disease Patients?
    Am J Gastroenterol. 2020;115.
    >> Share

  264. ERIC J
    P047 Awareness and Impact of Recent AGA Guideline Changes for Moderate to Severe Ulcerative Colitis Patients.
    Am J Gastroenterol. 2020;115.
    >> Share

  265. ERIC J
    P046 Though Biosimilar Infliximab Prescribing in Inflammatory Bowel Disease Has Increased, Branded Infliximab Continues to Be Prescribed More Often.
    Am J Gastroenterol. 2020;115.
    >> Share

  266. CASEY C, Jenny G, Michelle B, Joe L, et al
    P042 The CONCERT Initiative: Impact of Inflammatory Bowel Disease Care Referral Pathway.
    Am J Gastroenterol. 2020;115.
    >> Share

  267. SARA L, Millie L, Uma M
    P040 Indications for Cesarean Section in Pregnant Women with Inflammatory Bowel Disease: Results from the PIANO Registry.
    Am J Gastroenterol. 2020;115.
    >> Share

  268. SARA H, David H, Joe Z, Ryan H, et al
    P038 Factors Associated with Impaired Patient-Reported Outcomes and Work Productivity Among Patients with Ulcerative Colitis in Remission.
    Am J Gastroenterol. 2020;115.
    >> Share

  269. DAVID P, Caterina O, Christopher A, Gregory AC, et al
    P037 Efficacy and Safety of 1-L NER1006 Bowel Preparation in Patients with Inflammatory Bowel Disease: Analysis of 2 Phase 3 Studies.
    Am J Gastroenterol. 2020;115.
    >> Share

  270. CLARA U, Amanda T, Debora T, Giovana C, et al
    P036 Clinical and Psychological Factors Associated with Impaired Body Image in Patients with Inflammatory Bowel Disease.
    Am J Gastroenterol. 2020;115.
    >> Share

  271. KAUSTAV S, Austin T, Roman G, Allison M, et al
    P033 Demographic Factors Associated with Successful Telehealth Visits in Inflammatory Bowel Disease Patients.
    Am J Gastroenterol. 2020;115.
    >> Share

  272. WILLIAM S, Brian F, Stephen H, Severine V, et al
    P031 Ozanimod in Patients with Moderate-to-Severe Ulcerative Colitis: Long-Term Safety and Efficacy from the Phase 2 TOUCHSTONE Study 4-Year Open-Label Extension.
    Am J Gastroenterol. 2020;115.
    >> Share

  273. SILVIO D, Brian F, Stephen H, Igor J, et al
    P030 Ozanimod Efficacy, Safety, and Histology in Patients with Moderate-to-Severe Ulcerative Colitis During Maintenance in the Phase 3 True North Study.
    Am J Gastroenterol. 2020;115.
    >> Share

  274. EDWARD B, Harris A, Joe Z, Antoine S, et al
    P027 Factors Associated with Biologic Discontinuation in Patients with Inflammatory Bowel Disease in TARGET-IBD.
    Am J Gastroenterol. 2020;115.
    >> Share

  275. SHINTARO A, Jacob O, Cindy T, Victoria R, et al
    P026 Assessment of Contributing Factors for Fistula Development in Patients with Inflammatory Bowel Disease Treated by Proctocolectomy with Ileal Pouch-Anal Anastomosis.
    Am J Gastroenterol. 2020;115.
    >> Share

  276. WILLIAM S, Geert D, Doug W, Stephen H, et al
    P025 Ozanimod Efficacy, Safety, and Histology in Patients with Moderate-to-Severe Ulcerative Colitis During Induction in the Phase 3 True North Study.
    Am J Gastroenterol. 2020;115.
    >> Share

  277. GALIYA B, Alisa R, Maria L
    P024 Medical Decision Support System in the Diagnosis of Ulcerative Colitis.
    Am J Gastroenterol. 2020;115.
    >> Share

  278. MICHAEL C, Puza S, Benjamin C, Leonardo S, et al
    P021 Characteristics of Patients Treated with Tofacitinib for Ulcerative Colitis in the Real World: Findings from a Large US Claims Database.
    Am J Gastroenterol. 2020;115.
    >> Share

  279. SUBRATA G, Geert D, Vipul J, Florian R, et al
    P012 Ozanimod Reduced Fecal Calprotectin Levels in Patients with Ulcerative Colitis in the Phase 3 True North Study.
    Am J Gastroenterol. 2020;115.
    >> Share

  280. ROGERIO P, Julio C, Liliana C, Erika B, et al
    P008 Long-Term Effectiveness and Safety of Ustekinumab for The Treatment of Crohn s Disease: A Brazilian Multicentre Real-world Study.
    Am J Gastroenterol. 2020;115.
    >> Share

  281. OLEG K, Albina L, Anatoliy K, Anna K, et al
    P005 Overcoming Secondary Loss of Response to Infliximab in Patients With Ulcerative Colitis With the Use of Mesenchymal Stromal Cells.
    Am J Gastroenterol. 2020;115.
    >> Share

  282. OLEG K, Anna K, Albina L, Tatyana S, et al
    P002 Frequency and Causes of Prolongation of the Induction Course of Tofacitinib in Patients with Ulcerative Colitis.
    Am J Gastroenterol. 2020;115.
    >> Share

  283. ERNESTO R, Rachel H, Meera L, Pablo P, et al
    P001 North-South Gradient in the Incidence of Pediatric Inflammatory Bowel Disease Along the Atlantic Coast.
    Am J Gastroenterol. 2020;115.
    >> Share

    November 2020
  284. KHAN N, Patel D, Trivedi C, Kavani H, et al
    Incidence of Acute Myeloid Leukemia and Myelodysplastic Syndrome in Patients With Inflammatory Bowel Disease and the Impact of Thiopurines on Their Risk.
    Am J Gastroenterol. 2020 Nov 26. doi: 10.14309/ajg.0000000000001058.
    >> Share

  285. ZAVER HB, Ghoz H, Azar A, Alexander LF, et al
    Inferior Mesenteric Arteriovenous Malformation Masquerading as Ulcerative Colitis.
    Am J Gastroenterol. 2020 Nov 10. doi: 10.14309/ajg.0000000000000917.
    >> Share

  286. CHAPARRO M, Gordillo J, Domenech E, Esteve M, et al
    Fendrix vs Engerix-B for Primo-Vaccination Against Hepatitis B Infection in Patients With Inflammatory Bowel Disease: A Randomized Clinical Trial.
    Am J Gastroenterol. 2020;115:1802-1811.
    >> Share

  287. BANTY A, Melmed GY
    Improving Hepatitis B Virus Vaccination Responses in Inflammatory Bowel Disease: Does Greater Dose and Greater Frequency Lead to Greater Protection?
    Am J Gastroenterol. 2020;115:1797-1798.
    >> Share

  288. LITTLE DHW, Tabatabavakili S, Shaffer SR, Nguyen GC, et al
    Effectiveness of Dose De-escalation of Biologic Therapy in Inflammatory Bowel Disease: A Systematic Review.
    Am J Gastroenterol. 2020;115:1768-1774.
    >> Share

  289. WINDSOR JW, Underwood FE, Brenner E, Colombel JF, et al
    Data Visualization in the Era of COVID-19: An Interactive Map of the SECURE-IBD Registry.
    Am J Gastroenterol. 2020;115:1923-1924.
    >> Share

  290. CHAPUIS-BIRON C, Kirchgesner J, Pariente B, Bouhnik Y, et al
    Ustekinumab for Perianal Crohn's Disease: The BioLAP Multicenter Study From the GETAID.
    Am J Gastroenterol. 2020;115:1812-1820.
    >> Share

    October 2020
  291. BUCHNER AM, Schneider Y, Lichtenstein GR
    Biosimilars in Inflammatory Bowel Disease.
    Am J Gastroenterol. 2020 Oct 27. doi: 10.14309/ajg.0000000000000844.
    >> Share

  292. GUBATAN J, Nielsen OH, Levitte S, Juhl CB, et al
    Biologics During Pregnancy in Women With Inflammatory Bowel Disease and Risk of Infantile Infections: A Systematic Review and Meta-Analysis.
    Am J Gastroenterol. 2020 Oct 23. doi: 10.14309/ajg.0000000000000910.
    >> Share

  293. KHAN N, Patel D, Xie D, Pernes T, et al
    Are Patients With Inflammatory Bowel Disease at an Increased Risk of Developing SARS-CoV-2 than Patients Without Inflammatory Bowel Disease? Results From a Nationwide Veterans' Affairs Cohort Study.
    Am J Gastroenterol. 2020 Oct 19. doi: 10.14309/ajg.0000000000001012.
    >> Share

  294. ELTEN M, Benchimol EI, Fell DB, Kuenzig ME, et al
    Residential Greenspace in Childhood Reduces Risk of Pediatric Inflammatory Bowel Disease: A Population-Based Cohort Study.
    Am J Gastroenterol. 2020 Oct 8. doi: 10.14309/ajg.0000000000000990.
    >> Share

  295. FIORINO G, Gilardi D, Radice S, Furfaro F, et al
    Absence of COVID-19 Infection in Patients Accessing IBD Unit at Humanitas, Milan: Implications for Postlockdown Measures.
    Am J Gastroenterol. 2020;115:1719-1721.
    >> Share

  296. MANSOOR E, Khoudari G, Abou Saleh M, Elfadawy N, et al
    The Many Faces of COVID-19: Atypical Presentation of COVID-19 in a Patient With Crohn's Disease With Acute Diarrhea Leading to Severe Hypovolemic Hyponatremia-A Case Report.
    Am J Gastroenterol. 2020;115:1730-1731.
    >> Share

  297. GIESE-KIM N, Wu M, Dehghan M, Sceats LA, et al
    Home Infliximab Infusions Are Associated With Suboptimal Outcomes Without Cost Savings in Inflammatory Bowel Diseases.
    Am J Gastroenterol. 2020;115:1698-1706.
    >> Share

    September 2020
  298. CHAPARRO M, Gordillo J, Domenech E, Esteve M, et al
    Fendrix vs Engerix-B for Primo-Vaccination Against Hepatitis B Infection in Patients With Inflammatory Bowel Disease: A Randomized Clinical Trial.
    Am J Gastroenterol. 2020 Sep 30. doi: 10.14309/ajg.0000000000000926.
    >> Share

  299. BANTY A, Melmed GY
    Improving Hepatitis B Virus Vaccination Responses in Inflammatory Bowel Disease: Does Greater Dose and Greater Frequency Lead to Greater Protection?
    Am J Gastroenterol. 2020 Sep 25. doi: 10.14309/ajg.0000000000000921.
    >> Share

  300. DALAL RS, Palchaudhuri S, Snider CK, Gitelman Y, et al
    A Multimodal Intervention Using Nonopioid Analgesics Is Associated With Reduced Intravenous Opioid Exposure Among Hospitalized Patients With Inflammatory Bowel Diseases.
    Am J Gastroenterol. 2020;115:1474-1485.
    >> Share

  301. QUINN KP, Raffals LE
    An Update on the Medical Management of Inflammatory Pouch Complications.
    Am J Gastroenterol. 2020;115:1439-1450.
    >> Share

    August 2020
  302. NARULA N, Wong ECL, Aruljothy A, Dulai PS, et al
    Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial.
    Am J Gastroenterol. 2020;115:1236-1245.
    >> Share

    July 2020
  303. HAMMOUDI N, Auzolle C, Tran Minh ML, Boschetti G, et al
    Postoperative Endoscopic Recurrence on the Neoterminal Ileum But Not on the Anastomosis Is Mainly Driving Long-Term Outcomes in Crohn's Disease.
    Am J Gastroenterol. 2020;115:1084-1093.
    >> Share

    June 2020
  304. ROZICH JJ, Holmer A, Singh S
    Effect of Lifestyle Factors on Outcomes in Patients With Inflammatory Bowel Diseases.
    Am J Gastroenterol. 2020;115:832-840.
    >> Share

    May 2020
  305. BEWTRA M, Lichtenstein GR
    Mongersen and SMAD-7 Inhibition, Not a Lucky 7 for Patients With IBD: When Trial Design Is as Important as Disease Therapy.
    Am J Gastroenterol. 2020;115:687-688.
    >> Share

  306. LEE MW, Pourmorady JS, Laine L
    Use of Fecal Occult Blood Testing as a Diagnostic Tool for Clinical Indications: A Systematic Review and Meta-Analysis.
    Am J Gastroenterol. 2020;115:662-670.
    >> Share

    March 2020
  307. SHAH A, Macdonald GA, Morrison M, Holtmann G, et al
    Targeting the Gut Microbiome as a Treatment for Primary Sclerosing Cholangitis: A Conceptional Framework.
    Am J Gastroenterol. 2020 Mar 25. doi: 10.14309/ajg.0000000000000604.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016